Biomea Fusion Announces Acceptance of Three Abstracts for its Novel Menin Inhibitor Highlighting Durable Glycemic Control in Diabetes Patients at the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in 2024 - Biomea Fusion (NASDAQ:BMEA)
New clinical data from all dosing cohorts (n=62) initiated to date from the escalation portion of COVALENT-111 and long-term (26 weeks) follow-up data of the 200 mg dosed cohorts will be featured during an oral Poster
United States Chunyi Zhao Securities Exchange Biomea Fusion Inc Exchange Commission Poster Discussion Presentation
Source: benzinga.com